GSK reported Phase 3 bepirovirsen results for chronic hepatitis B that show a functional cure rate after stopping background nucleoside/nucleotide therapy. In two replicate trials (B-Well 1 and B-Well 2), 20% and 19% of bepirovirsen recipients achieved the study’s functional cure endpoint at week 72, versus no functional cures in placebo arms, after patients discontinued NA therapy at week 48. The NEJM-published data also highlighted tolerability signals: adverse events occurred in 91% of bepirovirsen patients versus 73% with placebo, with grade 3+ events in 16% and 3%, respectively. Elevated alanine aminotransferase was the most common grade 3 event. GSK frames the results as potentially redefining treatment goals for HBV, where functional cure remains the key unmet objective. Separately, GSK and Ionis also have a parallel hepatitis B strategy landscape emerging around antisense approaches, as investors increasingly weigh fixed-duration regimens that can convert immune control after treatment withdrawal.